
    
      This is a Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage
      (III/IV) and Recurrent Non-Small Cell Lung Cancer.

      Patients with histologically confirmed recurrent, advanced stage of lung cancer, and there
      are no other standard therapies available may be eligible to participate in this study.
    
  